Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MRTX source : Www.biospace.com save search
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Published: 2024-02-02 (Crawled : 14:30) - biospace.com/
RYZB | $62.49 0.03% 280K
|
|
| O: 0.03%
H: 0.11%
C: 0.0%
XYF | $3.78 -0.26% 0.0% 4.9K
|
Finance
|
| O: 1.04%
H: 1.79%
C: -1.23%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
financial results
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Published: 2024-01-23 (Crawled : 14:30) - biospace.com/
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: -0.07%
H: 1.38%
C: 1.25%
EVR | $185.29 -0.11% 0.0% 220K
|
Finance
|
| O: 0.35%
H: 0.29%
C: -0.26%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.22%
H: 1.49%
C: 0.89%
acquisition
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-06 (Crawled : 15:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.75%
H: 0.59%
C: 0.27%
therapeutics financial results
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published: 2023-10-31 (Crawled : 06:00) - biospace.com/
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: 0.83%
H: 0.0%
C: 0.0%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.25%
H: 0.54%
C: 0.29%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | $3.78 -0.26% 0.0% 4.9K
|
Finance
|
| O: -3.19%
H: 4.87%
C: 4.87%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -4.68%
H: 2.46%
C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.16%
H: 0.47%
C: 0.2%
financial results
Mirati Therapeutics Announces Pricing of Upsized Public Offering - August 09, 2023
Published: 2023-08-09 (Crawled : 11:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 23.42%
H: 8.46%
C: 6.87%
offering therapeutics
Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
Published: 2023-06-20 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -1.15%
H: 0.16%
C: -1.94%
krasg12 treatment system results
Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
Published: 2023-06-01 (Crawled : 22:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.89%
H: 1.36%
C: 0.49%
conference global therapeutics
Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference
Published: 2023-04-27 (Crawled : 22:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.44%
H: 0.66%
C: -0.21%
america conference health care therapeutics
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
Published: 2022-12-13 (Crawled : 11:00) - biospace.com/
QGEN | $39.47 0.61% 0.0% 950K
|
Health Technology
|
| O: 2.13%
H: 0.3%
C: -2.2%
QGEN | $39.47 0.61% 0.0% 950K
|
Health Technology
|
| O: 2.13%
H: 0.3%
C: -2.2%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.16%
H: 1.41%
C: 0.19%
fda lung diagnostic approval cancer
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO
Published: 2022-11-28 (Crawled : 17:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.43%
H: 2.28%
C: -3.4%
therapeutics results
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: -5.85%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
incb9928 collaboration trial therapeutics tumors agreement
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
Published: 2022-10-12 (Crawled : 13:00) - biospace.com/
AADI | $1.81 -0.55% -0.55% 150K
|
Manufacturing
|
| O: 3.7%
H: 0.0%
C: -7.64%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.14%
H: 5.61%
C: 5.46%
lung therapeutics tumors bioscience cancer
New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases
Published: 2022-06-06 (Crawled : 19:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 6.31%
H: 1.07%
C: -2.15%
krasg12 system cancer
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
VSTM | $10.19 -6.0% -6.38% 67K
|
Health Technology
|
| O: 3.05%
H: 0.74%
C: -9.63%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 6.31%
H: 1.07%
C: -2.15%
vs-6766 cancer defactinib ovarian cancer
Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
Published: 2022-04-27 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.21%
H: 0.88%
C: -2.15%
krasg12 research therapeutics asco cancer
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.42%
H: 5.52%
C: 4.35%
krasg12 new drug treatment fda application drug therapeutics cel food lung cancer cancer fda acceptance
BioSpace Movers & Shakers, Jan. 14
Published: 2022-01-14 (Crawled : 13:30) - biospace.com/
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.67%
H: 3.62%
C: 3.62%
PPG A | $135.11 0.11% -0.82% 2.3M
|
Process Industries
|
| O: -2.07%
H: 0.0%
C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
AMRX | $5.36 -1.83% -1.87% 840K
|
Health Technology
|
| O: -1.71%
H: 0.0%
C: 0.0%
PHAT | $9.5 -3.06% -3.16% 420K
|
Health Technology
|
| O: -3.08%
H: 0.0%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: 0.0%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
space spac
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
Published: 2021-12-02 (Crawled : 09:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -5.18%
H: 4.5%
C: 4.05%
Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers
Published: 2021-11-17 (Crawled : 13:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 1.02%
H: 0.86%
C: -1.77%
new drug food application cancer drug submission
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.